National Cancer Institute, Office of Biorepositories and Biospecimen Research, 31 Center Drive, Room 10A03, Bethesda, MD 20892, USA.
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):912-5. doi: 10.1158/1055-9965.EPI-10-0058. Epub 2010 Mar 16.
Variables introduced during the processes involved in biospecimen collection, processing, storage, and analysis are among the potential sources of bias in biomarker research. International efforts are under way to develop best practices to standardize biospecimen handling protocols. In general, documents on best practices address three major recurring themes: technical best practices on infrastructure and specimen handling, recommendations on informatics and data management, and recommendations on ethical, legal, and social issues. There are many areas of agreement among various international efforts, but no single set of practices has emerged as a unifying document. The ethical, legal, and social issues are particularly difficult to harmonize due to the many country-specific issues that are governed by a variety of local and federal rules and regulations. Given the increasingly international nature of research involving biomarkers and biospecimens, it will be necessary to continue to cooperate in the development of harmonized evidence-based best practices. Several international organizations including the International Cancer Genome Consortium are engaged in such efforts.
在生物样本采集、处理、存储和分析过程中引入的变量是生物标志物研究中潜在的偏倚来源之一。国际上正在努力制定最佳实践,以标准化生物样本处理协议。一般来说,关于最佳实践的文件涉及三个主要的反复出现的主题:基础设施和样本处理方面的技术最佳实践、关于信息学和数据管理的建议,以及关于伦理、法律和社会问题的建议。各种国际努力之间有许多共识领域,但没有一套实践能够作为统一的文件出现。由于许多国家特定的问题受到各种地方和联邦规则和法规的管辖,因此,伦理、法律和社会问题特别难以协调。鉴于涉及生物标志物和生物样本的研究日益具有国际性,有必要继续合作制定协调一致的基于证据的最佳实践。包括国际癌症基因组联盟在内的几个国际组织正在开展此类工作。